A three-drug medication known as a “polypill,” developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population.
In a move that has the potential to change the future of surgery, advance quality care, and bring economic growth to New York City, Mount Sinai Health System announced today the launch of the Comprehensive Center for Surgical Innovation (CCSI).
Mount Sinai Health System today announced that Crain’s New York Business Journal has named four of its leaders to its 2022 Notable Health Care Leaders list.
Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai have launched a new human genome sequencing research project called the Mount Sinai Million Health Discoveries Program with the Regeneron Genetics Center (RGC), part of the industry-leading, New York-based biotechnology company Regeneron.
Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open on August 11, 2022.
In a study published today in the Journal of General Internal Medicine, researchers at the Icahn School of Medicine at Mount Sinai paint a first-of-its-kind nationally representative portrait of the health care needs of older homebound Americans. An estimated 2 million strong and growing, this population has been at once invisible and extremely costly to the health care system. The researchers point to a home-based care model as the solution to better care and a more efficient allocation of health care dollars.
The Mount Sinai Health System announced today data from an innovative medical-legal pilot program that proactively identifies and provides free, civil legal services to patients in underserved communities who have unaddressed legal needs to improve their health outcomes.
Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer® (SU2C) to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.
The Icahn School of Medicine at Mount Sinai announced today the appointment of three new Laureates as part of its Biomedical Laureates Program, furthering its institutional commitment to broadening diversity and mentorship opportunities.
Mount Sinai researchers have achieved an unprecedented understanding of the genetic and molecular machinery in human microglia—immune cells that reside in the brain—that could provide valuable insights into how they contribute to the development and progression of Alzheimer’s disease (AD). The team’s findings were published in Nature Genetics.
A team of researchers at the Icahn School of Medicine at Mount Sinai has identified a therapeutic target for the preservation and regeneration of beta cells (β cells)—cells in the pancreas that produce and distribute insulin.
The Jack Martin Fund (JMF) has built on its partnership with the Mount Sinai Health System to provide cutting-edge care and support to children with cancer through a new $3.5 million gift to The Mount Sinai Hospital to establish the Jack Martin Fund Child and Adolescent Imaging Center at Mount Sinai Kravis Children’s Hospital.
Mount Sinai Health System and Contessa, the leading comprehensive home-based care provider, announced the extension of their partnership combining Mount Sinai South Nassau’s home health agency into their existing joint venture. The new combination offers a full continuum of home-based care that includes home health, hospitalization at home, rehabilitation at home (in lieu of care at a skilled nursing facility) and palliative care at home. The home health agency will be called Mount Sinai at Home.
In a race against time to cure childhood brain cancer, the leading cause of cancer deaths among children, Mount Sinai Kravis Children’s Hospital is forming the Mount Sinai Children’s Brain and Spinal Tumor Center.
The Mount Sinai Hospital’s Department of Geriatrics was ranked No. 1 in the nation by U.S. News & World Report for the third consecutive year. The Mount Sinai Hospital was also listed on the “Honor Roll” of the nation’s top 20 hospitals for the seventh year in a row.
Black patients have a dramatically higher risk of advanced vision loss after a new diagnosis of primary open angle glaucoma (POAG) when compared to white patients, according to a new study from New York Eye and Ear Infirmary of Mount Sinai (NYEE).
Treating liver cancer tumors to shrink them in order to allow the patient to qualify for a liver transplant leads to excellent 10-year post-transplant outcomes, according to new Mount Sinai research published in JAMA Surgery. The results validate current national policies around transplant eligibility.
Patients with a specific form of age-related macular degeneration (AMD), a leading cause of blindness in the United States, are at significant risk for cardiovascular disease and stroke, according to new research from New York Eye and Ear Infirmary of Mount Sinai.
A unique Mount Sinai study focused on a multi-ethnic, underserved community in New York City shows that young Black adults are twice as likely to have atherosclerosis as similarly situated young Hispanic adults.
The growing incidence of a potentially cancer-causing liver disease in children is associated with prenatal exposure to several endocrine-disrupting chemicals, Mount Sinai researchers report.
Mount Sinai-led researchers have shown that tiny, robust immune particles derived from the blood of a llama could provide strong protection against every COVID-19 variant, including Omicron, and 18 similar viruses.
Mount Sinai researchers have conducted one of the first studies to show the acute effect of obstructive sleep apnea on Alzheimer’s disease biomarkers, and the ability to even measure Alzheimer's disease biomarkers from blood.
A new study from the Icahn School of Medicine at Mount Sinai quantifies the cardiovascular risk posed by exposure to specific environmental factors, showing, for example, that air pollution heightens the risk of heart disease mortality by 17 percent.
Mount Sinai Health System is proud to announce that Kenneth L. Davis, MD, Chief Executive Officer, is among the 2022 class of Modern Healthcare’s 50 Most Influential Clinical Executives award.
Mount Sinai researchers have developed a machine learning algorithm that can determine if an individual has SARS-CoV-2 infections, the virus that causes COVID-19—with a high sensitivity and specificity—from the data collected by wearable devices.
Nina Bhardwaj, MD, PhD, Director of Immunotherapy at The Tisch Cancer Institute at Mount Sinai, has received the 2022 Lifetime Achievement in Cancer Research award from the American Association of Indian Scientists in Cancer Research (AAISCR).
Mount Sinai to lead discussions on transgender health, psychedelic therapeutics and long COVID at the 2022 Aspen Ideas: Health and Aspen Ideas Festival.
Mount Sinai researchers have for the first time identified genes that predict a good response to a vital new therapy for a blood cancer that can have serious side effects for some patients.
Mount Sinai researchers have developed a rapid blood assay that measures the magnitude and duration of someone’s immunity to SARS-CoV-2, the virus that causes COVID-19. This test will allow large-scale monitoring of the population’s immunity and the effectiveness of current vaccines to help design revaccination strategies for vulnerable immunosuppressed individuals, according to a study published in Nature Biotechnology in June.
Mount Sinai Brooklyn has earned The Joint Commission’s Gold Seal of Approval ® and the American Stroke Association’s Heart-Check mark for Advanced Primary Stroke Center Certification.
Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than an invasive tumor biopsy procedure. Their study was published in the Journal of Experimental & Clinical Cancer Research in June.
Researchers from the Icahn School of Medicine at Mount Sinai have applied a novel stem cell model to map disease risk variants in human neurons, which could help provide insights into the biological mechanisms that underlie neuropsychiatric disorders such as autism and schizophrenia.
Researchers at the Icahn School of Medicine at Mount Sinai have been awarded an initial $16 million from the National Institutes of Health (NIH) to discover and develop globally accessible and affordable novel oral antivirals to combat COVID-19 and future pandemics.
Researchers from the Brain Injury Research Center at the Icahn School of Medicine at Mount Sinai, in partnership with the Pennsylvania Department of Corrections (PADOC) and the Brain Injury Assocation of Pennsylvania (BIAPA), have launched a rigorous research study to reduce recidivism, or re-offending, among people with brain injury who are leaving incarceration.
Prolonged delays in breast cancer screening related to the COVID-19 pandemic have led to delayed diagnosis, poor health outcomes, and an increase in disparities. To address this, Mount Sinai Health System has launched “Mammogram May” to empower women to take charge of their breast health by scheduling an annual mammogram.
An advanced radiotherapy technique called radiation segmentectomy may be effective against very early to early-stage hepatocellular carcinoma (HCC), a type of liver cancer that cannot be treated surgically or thermally.